There is new evidence for "abandoning" statins

There is new evidence for "abandoning" statins

September 28, 2018 Source: Chinese Journal of Science and Technology

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Recently, a review article by 17 doctors from the United States, Ireland, Italy, Sweden, France and Japan stated that high cholesterol or "bad" cholesterol levels have nothing to do with heart disease, and asked doctors to "give up" to use statins. drug.

High levels of low-density lipoprotein cholesterol (LDL-C) have long been recognized as one of the leading causes of heart disease and one of the leading “killers” of heart disease.

However, a new study based on data from approximately 1.3 million patients shows that statins have "suspicious benefits" as the primary means of treating heart disease. The paper was published recently in the journal Clinical Pharmacology Expert Review.

The article raises objections to some review comments on statins, which the authors consider to be "misleading statistics because they remove failed experiments and ignore many conflicting observations." They also concluded that statin therapy has many serious side effects and that these have been "minimized" by some trials.

The authors include Sherif Sultan, professor of the International Society of Vascular Surgery in Galway, Ireland, Dr. Malcolm Kendrick, author of The Great Cholesterol Con, and Dr. David M Diamond, a neuroscientist and cardiovascular disease researcher in the United States.

Among them, Professor Sherif Sultan said that despite unproven benefits and serious side effects, millions of people around the world are taking statins, including many people without a history of heart disease.

"We recommend that clinicians abandon the use of statins and PCSK-9 inhibitors, but to judge and treat the causes of cardiovascular disease," Sultan said. PCSK-9 inhibitors are a relatively new class of cholesterol-lowering treatments that are currently being widely marketed at a cost of about 20,000 euros per year.

Regarding whether cholesterol-lowering treatment can reduce the risk of cardiovascular disease, the article stated that the new regulations proposed by the European and American health authorities in 2005 allowed all test data to be made public. The study showed that between 2000 and 2012, the use of statins in 12 European countries was not associated with reduced mortality.

Moreover, experts found that in the general population, high "bad" cholesterol levels appear to be unrelated to cardiovascular risk, even familial hypercholesterolemia (a hereditary disease characterized by high LDL-C levels) Individuals are not related to their risk of illness.

The authors say the benefits of using cholesterol-lowering drugs are questionable. They found that high total cholesterol was not associated with atherosclerosis (arteriosclerosis), and four studies confirmed a lack of association between LDL-C and atherosclerosis.

At the same time, they found that patients with acute myocardial infarction had lower than normal levels of cholesterol, while healthy people with low "bad" cholesterol levels had a significantly increased risk of infectious diseases and cancer.

Sultan also introduced one of the most striking findings, with older LDL-C older people living longer.

For patients who already have a high risk of heart disease, experts agree that statins, especially those with a heart attack or stroke, have proven to be “lifeguards” and can reduce the chance of recurrence.

However, it is important to note that patients who have taken statins should continue to take them. If you have any concerns, please consult a professional doctor. (Wang Fei)

Related paper information: https://doi.org/10.1080/17512433.2018.1519391

Chinese Journal of Science (2018-09-28 8th Edition Health)

Guangzhou Zhongzhinan Supply Chain Co.,Ltd. , https://www.gzzhongzhinan.com